The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; ...
WALTHAM, Mass.--(BUSINESS WIRE)--To increase researchers’ access to comprehensive data, Wolters Kluwer, Health has expanded Ovid® with SRI International’s BioCyc™, a collection of more than 20,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results